ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis

被引:204
作者
Darsow, U. [1 ,2 ]
Wollenberg, A. [3 ]
Simon, D. [4 ]
Taieb, A. [5 ]
Werfel, T. [6 ]
Oranje, A. [7 ]
Gelmetti, C. [8 ]
Svensson, A. [9 ]
Deleuran, M. [10 ]
Calza, A-M [11 ]
Giusti, F. [12 ]
Luebbe, J. [11 ]
Seidenari, S. [12 ]
Ring, J. [1 ]
机构
[1] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-8000 Munich, Germany
[2] Helmholtz Ctr TUM, Div Environm Dermatol & Allergy, Munich, Germany
[3] Univ Munich, Dept Dermatol & Allergy, Munich, Germany
[4] Univ Bern, Inselspital, Dept Dermatol, Univ Hosp Bern, CH-3010 Bern, Switzerland
[5] Hop St Andre, Serv Dermatol, Bordeaux, France
[6] Hautklin Linden, Dept Dermatol MHH, Hannover, Germany
[7] Erasmus MC, Dept Pediat, Pediat Dermatol Unit, Rotterdam, Netherlands
[8] Inst Clin Dermatol Prima & Dermatol Pediat, Milan, Italy
[9] Univ Hosp UMAS, Dept Dermatol, Malmo, Sweden
[10] Aarhus Univ Hosp, Dept Dermatol, DK-8000 Aarhus, Denmark
[11] Hop Cantonal Univ Geneva, Dermatol Clin, Geneva, Switzerland
[12] Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy
关键词
atopic dermatitis; eczema; guideline; therapy; TESTING ENHANCES IDENTIFICATION; PIMECROLIMUS CREAM 1-PERCENT; PLACEBO-CONTROLLED TRIAL; COMBINED SKIN PRICK; WET-WRAP DRESSINGS; STAPHYLOCOCCUS-AUREUS; TACROLIMUS OINTMENT; DOUBLE-BLIND; PATCH TEST; MYCOPHENOLATE-MOFETIL;
D O I
10.1111/j.1468-3083.2009.03415.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The diagnosis of atopic dermatitis (AD) is made using evaluated clinical criteria. Management of AD must consider the symptomatic variability of the disease. Methods EADV eczema task force developed its guideline for atopic dermatitis diagnosis and treatment based on literature review and repeated consenting group discussions. Results and Discussion Basic therapy relies on hydrating topical treatment and avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment based on topical glucocorticosteroids and topical calcineurin antagonists is used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, but the topical calcineurin inhibitors, tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection may induce disease exacerbation and can justify additional antimicrobial/antiseptic treatment. Systemic antihistamines (H1) can relieve pruritus, but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength or UVB 311 nm. Dietary recommendations should be specific and given only in diagnosed individual food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Stress-induced exacerbations may make psychosomatic counselling recommendable. 'Eczema school' educational programmes have been proven to be helpful.
引用
收藏
页码:317 / 328
页数:12
相关论文
共 135 条
[1]   Increasing incidence of streptococcal impetigo in atopic dermatitis [J].
Adachi, J ;
Endo, K ;
Fukuzumi, T ;
Tanigawa, N ;
Aoki, T .
JOURNAL OF DERMATOLOGICAL SCIENCE, 1998, 17 (01) :45-53
[2]   Atopic dermatitis: Systemic [J].
Akhavan, Arash ;
Rudikoff, Donald .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2008, 27 (02) :151-155
[3]   Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis [J].
Arellano, Felix M. ;
Wentworth, Charles E. ;
Arana, Alejandro ;
Fernandez, Carlos ;
Paul, Carle F. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (04) :808-816
[4]   Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study [J].
Berth-Jones, J ;
Damstra, RJ ;
Golsch, S ;
Livden, JK ;
Van Hooteghem, O ;
Allegra, F ;
Parker, CA .
BRITISH MEDICAL JOURNAL, 2003, 326 (7403) :1367-1370
[5]   Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial [J].
Berth-Jones, J ;
Takwale, A ;
Tan, E ;
Barclay, G ;
Agarwal, S ;
Ahmed, I ;
Hotchkiss, K ;
Graham-Brown, RAC .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (02) :324-330
[6]   Cyclosporine in severe childhood atopic dermatitis: A multicenter study [J].
BerthJones, J ;
Finlay, AY ;
Zaki, I ;
Tan, B ;
Goodyear, H ;
LewisJones, S ;
Cork, MJ ;
Bleehen, SS ;
Salek, MS ;
Allen, BR ;
Friedmann, P ;
Harper, J ;
Camp, RDR ;
Smith, S ;
GrahamBrown, RAC .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (06) :1016-1021
[7]   Standardization of double-blind, placebo-controlled food challenges [J].
Bindslev-Jensen, C .
ALLERGY, 2001, 56 :75-77
[8]   Macrolactam immunomodulators for topical treatment of inflammatory skin diseases [J].
Bornhövd, E ;
Burgdorf, WHC ;
Wollenberg, A .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (05) :736-743
[9]  
Bornhovd Elke C, 2002, Curr Opin Investig Drugs, V3, P708
[10]   Oat sensitization in children with atopic dermatitis:: prevalence, risks and associated factors [J].
Boussault, P. ;
Leaute-Labreze, C. ;
Saubusse, E. ;
Maurice-Tison, S. ;
Perromat, M. ;
Roul, S. ;
Sarrat, A. ;
Taieb, A. ;
Boralevi, F. .
ALLERGY, 2007, 62 (11) :1251-1256